Literature DB >> 31026503

Quinidine-A legacy within the modern era of antiarrhythmic therapy.

Laura Vitali Serdoz1, Harald Rittger2, Francesco Furlanello3, Dirk Bastian2.   

Abstract

Quinidine has a very long history as antiarrhythmic medication. The alkaloid has been used in the treatment of almost all cardiac arrhythmias, especially atrial fibrillation, since the early twentieth century. Despite decreases in clinical prescription over the last two decades, mainly due to side effects like pro-arrhythmia, leading to increased mortality and to the availability of newer anti-arrhythmic drugs and catheter ablation, Quinidine remains an invaluable drug in the modern era of antiarrhythmic therapy. We present a review of the pharmacological properties of quinidine and its pivotal therapeutic role in the treatment of life-threatening arrhythmic storms in patients with congenital arrhythmogenic syndromes like Brugada's syndrome, early repolarization syndrome, short QT syndrome and idiopathic ventricular fibrillation.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiarrhythmic drug therapy; Brugada syndrome; Channellopathies; Implantable cardioverter defibrillator; Primary electrical disease; Quinidine; Sudden cardiac death; Syncope; Ventricular fibrillation

Mesh:

Substances:

Year:  2019        PMID: 31026503     DOI: 10.1016/j.phrs.2019.04.028

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  4 in total

Review 1.  [Long and short QT syndromes : Emergency treatment and secondary prophylaxis].

Authors:  N Horn; N Rüb; C Wolpert
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2020-02-05

2.  Impact of Antiarrhythmic Drugs on the Outcome of Short QT Syndrome.

Authors:  Ibrahim El-Battrawy; Johanna Besler; Xin Li; Huan Lan; Zhihan Zhao; Volker Liebe; Rainer Schimpf; Siegfried Lang; Christian Wolpert; Xiaobo Zhou; Ibrahim Akin; Martin Borggrefe
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

3.  Insights into the Cardiotoxic Effects of Veratrum Lobelianum Alkaloids: Pilot Study.

Authors:  Amir Taldaev; Roman P Terekhov; Elizaveta V Melnik; Maria V Belova; Sergey V Kozin; Andrey A Nedorubov; Tatyana Ya Pomerantseva; Galina V Ramenskaya
Journal:  Toxins (Basel)       Date:  2022-07-15       Impact factor: 5.075

4.  Treatment of Erythroid Precursor Cells from β-Thalassemia Patients with Cinchona Alkaloids: Induction of Fetal Hemoglobin Production.

Authors:  Cristina Zuccato; Lucia Carmela Cosenza; Matteo Zurlo; Ilaria Lampronti; Monica Borgatti; Chiara Scapoli; Roberto Gambari; Alessia Finotti
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.